Ionis Pharmaceuticals Inc
F:ISI

Watchlist Manager
Ionis Pharmaceuticals Inc Logo
Ionis Pharmaceuticals Inc
F:ISI
Watchlist
Price: 66.06 EUR -0.06%
Market Cap: 9.6B EUR

Net Margin

-26.5%
Current
Improving
by 22.4%
vs 3-y average of -49%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-26.5%
=
Net Income
$-256.3m
/
Revenue
$967m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-26.5%
=
Net Income
€-256.3m
/
Revenue
$967m

Peer Comparison

Country Company Market Cap Net
Margin
US
Ionis Pharmaceuticals Inc
NASDAQ:IONS
12.3B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.7B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 77% of companies in the United States of America
Percentile
23rd
Based on 15 072 companies
23rd percentile
-26.5%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Ionis Pharmaceuticals Inc
Glance View

Market Cap
9.6B EUR
Industry
Biotechnology

In the realm of pharmaceutical innovation, Ionis Pharmaceuticals Inc. has carved a niche defined by its pioneering efforts in antisense technology. Founded in 1989, Ionis stands as a trailblazer in the development of RNA-targeted therapies, which deviate from the traditional drug development pathways by focusing on genetic solutions. The company specializes in antisense oligonucleotides—short, synthetic strands of DNA or RNA designed to bind selectively to specific messenger RNA (mRNA). By doing so, they aim to modulate the expression of genes associated with various diseases. This unique approach allows Ionis to address ailments at the genetic level, potentially preventing the production of disease-causing proteins, thus offering alternative therapeutic options for serious diseases. Ionis Pharmaceuticals monetizes its scientific breakthroughs through a diverse revenue stream model. It engages in multiple collaborative partnerships with major pharmaceutical companies, such as Biogen and AstraZeneca, which provide upfront payments, milestone-based fees, and royalties on lucrative antisense drugs that emerge from these alliances. Furthermore, Ionis holds an extensive internal pipeline, advancing proprietary drugs through various stages of research and clinical trials. By strategically balancing in-house projects with external collaborations, Ionis capitalizes on its innovative platform while mitigating financial risks. This dual-strategy not only sustains the company financially but positions it at the forefront of personalized medicine, potentially revolutionizing the landscape of therapeutic development.

ISI Intrinsic Value
29.55 EUR
Overvaluation 55%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-26.5%
=
Net Income
$-256.3m
/
Revenue
$967m
What is Ionis Pharmaceuticals Inc's current Net Margin?

The current Net Margin for Ionis Pharmaceuticals Inc is -26.5%, which is above its 3-year median of -49%.

How has Net Margin changed over time?

Over the last 3 years, Ionis Pharmaceuticals Inc’s Net Margin has decreased from 0.8% to -26.5%. During this period, it reached a low of -66.6% on Sep 30, 2023 and a high of 0.8% on Aug 30, 2022.

Back to Top